Literature DB >> 18958367

Nerve growth factor, sphingomyelins, and sensitization in sensory neurons.

Grant D Nicol1.   

Abstract

Because nerve growth factor (NGF) is elevated during inflammation, plays a causal role in the initiation of hyperalgesia, and is known to activate the sphingomyelin signalling pathway, we examined whether NGF and its putative second messenger, ceramide, could modulate the excitability of capsaicin-sensitive adult sensory neurons. Using the whole-cell patch-clamp recording technique, exposure of isolated sensory neurons to either 100 ng/mL NGF or 1 mmol/L N-acetyl sphingosine (C2-ceramide) produced a 3-4 fold increase in the number of action potentials (APs) evoked by a ramp of depolarizing current in a time-dependent manner. Intracellular perfusion with bacterial sphingomyelinase (SMase) also increased the number of APs suggesting that the release of native ceramide enhanced neuronal excitability. Glutathione, an inhibitor of neutral SMase, completely blocked the NGF-induced augmentation of AP firing, whereas dithiothreitol, an inhibitor of acidic SMase, was without effect. In the presence of glutathione and NGF, exogenous ceramide still enhanced the number of evoked APs, indicating that the sensitizing action of ceramide was downstream of NGF. To investigate the mechanisms of actions for NGF and ceramide, isolated membrane currents were examined. Both NGF and ceramide facilitated the peak amplitude of the TTX-resistant sodium current (TTX-R I(Na)) by approximately 1.5-fold and shifted the activation to more hyperpolarized voltages. In addition, NGF and ceramide suppressed an outward potassium current (I(K)) by ~35%. The inflammatory prostaglandin, PGE2, produced an additional suppression of I(K) after exposure to ceramide (~35%), suggesting that these agents might act on different targets. Based on the existing literature, it is not clear whether this NGF-induced sensitization is mediated by the high-affinity TrkA receptor or the low-affinity p75 neurotrophin receptor. Pretreatment with the p75 blocking antibody completely prevents the NGF-induced increase in the number of APs evoked by the current ramp. Although the sensitization by NGF was blocked, the antibody had no effect on the capacity of ceramide, a putative downstream signalling molecule, to enhance the excitability. Ceramide can be metabolized by ceramidase to sphingosine (Sph) and Sph to sphingosine 1-phosphate (S1P) by sphingosine kinase. It is well established that each of these products of sphingomyelin metabolism can act as intracellular signalling molecules. This raises the question as to whether the enhanced excitability produced by NGF was mediated directly by ceramide or required additional metabolism to Sph and/or S1P. Sph applied externally did not affect the neuronal excitability whereas internally perfused Sph augmented the number of APs evoked by the depolarizing ramp. Furthermore, internally perfused S1P enhanced the number of evoked APs. This sensitizing action of NGF, ceramide, and internally perfused Sph, were abolished by dimethylsphingosine (DMS), an inhibitor of sphingosine kinase. In contrast, internally perfused S1P enhanced the number of evoked APs in the presence of DMS. These observations support the idea that the metabolism of ceramide/Sph to S1P is critical for the sphingolipid-induced modulation of excitability. Thus, our findings indicate that the pro-inflammatory agent, NGF, can rapidly enhance the excitability of sensory neurons. This NGF-induced sensitization is mediated by activation of the sphingomyelin signalling pathway wherein intracellular S1P derived from ceramide, acts as an internal second messenger to regulate membrane excitability, however, the effector system whereby S1P modulates excitability remains undetermined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18958367

Source DB:  PubMed          Journal:  Sheng Li Xue Bao        ISSN: 0371-0874


  8 in total

Review 1.  Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis.

Authors:  Norman J Haughey; Veera V R Bandaru; Mihyun Bae; Mark P Mattson
Journal:  Biochim Biophys Acta       Date:  2010-05-07

2.  Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice.

Authors:  Nino Tabatadze; Alena Savonenko; Hongjun Song; Veera Venkata Ratnam Bandaru; Michael Chu; Norman J Haughey
Journal:  J Neurosci Res       Date:  2010-10       Impact factor: 4.164

3.  Sphingosine-1-phosphate acting via the S1P₁ receptor is a downstream signaling pathway in ceramide-induced hyperalgesia.

Authors:  Tim Doyle; Zhoumou Chen; Lina M Obeid; Daniela Salvemini
Journal:  Neurosci Lett       Date:  2011-05-13       Impact factor: 3.046

Review 4.  The roles of neutral sphingomyelinases in neurological pathologies.

Authors:  Charles R Horres; Yusuf A Hannun
Journal:  Neurochem Res       Date:  2012-01-12       Impact factor: 3.996

5.  The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.

Authors:  Kali Janes; Joshua W Little; Chao Li; Leesa Bryant; Collin Chen; Zhoumou Chen; Krzysztof Kamocki; Timothy Doyle; Ashley Snider; Emanuela Esposito; Salvatore Cuzzocrea; Erhard Bieberich; Lina Obeid; Irina Petrache; Grant Nicol; William L Neumann; Daniela Salvemini
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

Review 6.  Neurotrophins and target interactions in the development and regulation of sympathetic neuron electrical and synaptic properties.

Authors:  Jason A Luther; Susan J Birren
Journal:  Auton Neurosci       Date:  2009-09-13       Impact factor: 3.145

7.  Recruitment of sphingosine kinase to presynaptic terminals by a conserved muscarinic signaling pathway promotes neurotransmitter release.

Authors:  Jason P Chan; Zhitao Hu; Derek Sieburth
Journal:  Genes Dev       Date:  2012-05-15       Impact factor: 11.361

8.  Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

Authors:  Shaness A Grenald; Timothy M Doyle; Hong Zhang; Lauren M Slosky; Zhoumou Chen; Tally M Largent-Milnes; Sarah Spiegel; Todd W Vanderah; Daniela Salvemini
Journal:  Pain       Date:  2017-09       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.